```
=> id
ID IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> d
L1 HAS NO ANSWERS
L1              STR
```




```
Structure attributes must be viewed using STN Express query preparation.


=> s l1 full
   REG1stRY INITIATED
Substance data SEARCH and crossover from CAS REGISTRY in progress...
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.




FULL SEARCH INITIATED 12:33:45 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -  1229379 TO ITERATE

 81.3% PROCESSED  1000000 ITERATIONS                              6 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.17

FULL FILE PROJECTIONS:  ONLINE  **INCOMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:      1229379 TO  1229379
PROJECTED ANSWERS:               6 TO       15

L2            6 SEA SSS FUL L1
```

L3 2 L2

=> d 1-2 ibib abs hitstr

L3 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:1117984 CAPLUS
DOCUMENT NUMBER: 144:22625
TITLE: N-Sulfonylbenzotriazoles as advantageous reagents for C-sulfonylation
AUTHOR(S): Katritzky, Alan R.; Abdel-Fattah, Ashraf A. A.; Vakulenko, Anatoliy V.; Tao, Hui
CORPORATE SOURCE: Center for Heterocyclic Compounds Department of Chemistry, University of Florida, Gainesville, FL, 32611-7200, USA
SOURCE: Journal of Organic Chemistry (2005), 70(23), 9191-9197
CODEN: JOCEAH; ISSN: 0022-3263
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 144:22625
AB Reactions of readily available N-(alkyl-, aryl-, and heteroarylsulfonyl)benzotriazoles with diverse nitriles, reactive heteroaroms., alkylheteroaroms., sulfones, and esters produced α-cyanoalkyl sulfones, sulfonylheteroaroms., α-(sulfonylalkyl)heterocycles, α-sulfonylalkyl sulfones, and esters of α-sulfonyl acids, resp., in synthetically useful to excellent yields. The results represent examples of the successful application of sulfonylazoles for C-sulfonylation.
IT 866250-91-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of α-cyanoalkyl, heteroaryl, α-sulfonylalkyl, heteroarylalkyl sulfones, and α-sulfonyl esters via sulfonylation of nitriles, heterocycles, alkylheterocycles, alkylsulfones, or esters with N-sulfonylbenzotriazoles)
RN 866250-91-1 CAPLUS
CN Pyridine, 2-[phenyl(phenylsulfonyl)methyl]- (CA INDEX NAME)



REFERENCE COUNT: 81 THERE ARE 81 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:395089 CAPLUS
DOCUMENT NUMBER: 142:447221
TITLE: Preparation of 5-substituted

2-((phenylmethyl)thio)-4-phenyl-4H-1,2,4-triazole derivatives as GABA-agonists for the treatment of urinary incontinence

INVENTOR(S): Bauser, Marcus; Krueger, Joachim; Meier, Heinrich; Voehringer, Verena; Beyreuther, Bettina; Mogi, Muneto; Marumo, Makiko; Tsuno, Naoki; Shimizu, Haruka; Fujishima, Hiroshi; Yuasa, Hiroaki; Hayashi, Mayumi; Umeda, Masaomi; Iwata, Atsuko

PATENT ASSIGNEE(S): Bayer Healthcare A.-G., Germany

SOURCE: PCT Int. Appl., 113 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005039569	A1	20050506	WO 2004-EP11101	20041005
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2542682	A1	20050506	CA 2004-2542682	20041005
EP 1677786	A1	20060712	EP 2004-790125	20041005
R: DE, ES, FR, GB, IT				
JP 2007509045	T	20070412	JP 2006-534642	20041005

PRIORITY APPLN. INFO.: EP 2003-23701 A 20031018
WO 2004-EP11101 W 20041005

OTHER SOURCE(S): CASREACT 142:447221; MARPAT 142:447221

GI



I

AB Title compds. I [R1 = alkoxy, amino, alkylamino, etc.; R2 = acyl, alkyl,

etc.; R3-4 = H, halo, CN, etc.; R5 = H, OH, alkoxy, etc.; R6-7 = H, morpholino, etc.; X = divalent alkyl, NH, SO0-2] are prepared For instance, 3-(3-cyclopropyl-5-thioxo-1,5-dihydro-4H-1,2,4-triazol-4-yl)benzoic acid is reacted with bromodiphenylmethane (DMF, K2CO3, 60°, 16 h) to give 3-(3-(benzyhydrylsulfanyl)-5-cyclopropyl[1,2,4]triazol-4-yl)benzoic acid (II). II exhibits activity in a GABAb assay with an IC50 > 0.1 μM and ≤ 0.5 μM. I are useful for the treatment of overactive bladder, urinary incontinence such as urge urinary incontinence, benign prostatic hyperplasia (BPH), chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, or nerve injury.

IT 851293-82-8P 851293-94-2P 851294-00-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 5-substituted 2-((phenylmethyl)thio)-4-Ph-4H-1,2,4-triazole derivs. as GABA-agonists for treatment of urinary incontinence)

RN 851293-82-8 CAPLUS
CN Benzenamine, 4-[3-cyclopropyl-5-[(phenyl-3-pyridinylmethyl)thio]-4H-1,2,4-triazol-4-yl]-N,N-dimethyl- (CA INDEX NAME)



RN 851293-94-2 CAPLUS
CN Benzenamine, 4-[3-cyclopropyl-5-[(phenyl-2-pyridinylmethyl)thio]-4H-1,2,4-triazol-4-yl]-N,N-dimethyl- (CA INDEX NAME)



RN 851294-00-3 CAPLUS
CN Benzenamine, 4-[3-cyclopropyl-5-[(phenyl-4-pyridinylmethyl)thio]-4H-1,2,4-triazol-4-yl]-N,N-dimethyl- (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT